Coya’s focus is on generating safe, tolerable, and efficacious therapeutics that minimally burden the patient and caregiver and exponentially improve outcomes over the current standard of care
A 5-minute infusion in an outpatient facility with patients leaving the office within 1 – 2 hours. Proprietary technology enables multiple infusions over the course of the year
A limiting feature of Tregs has been their instability and inability to cryopreserve for maintenance therapy. Coya has perfected this process allowing a patient to be treated long term with highly viable and neuroprotective cells
Proprietary Platform Technology and Scalable Manufacturing Process Overcomes Supply Chain Management Barriers
TAI™ (Tregs Against Inflammation) platform offers potential therapeutic approaches to address the unmet and significant medical needs of patients with ALS, Parkinson’s, Alzheimer’s, FTD and other neurodegenerative and autoimmune diseases.
Dr. Stanley Appel “Patients with neurodegenerative diseases are in desperate need of transformative therapeutic options; harnessing the neuro-protective effects of Treg cell therapy shows great promise in unlocking a new treatment paradigm and will enable us to revolutionize care for patients with devastating neurodegenerative diseases.”